No Data
No Data
Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)
WPRT, FIVN and FATE Are Among After Hour Movers
Fate Therapeutics Prices $100 Million Offering, Private Placement
Fate Therapeutics (FATE) said Tuesday it has priced an underwritten offering of about 14.5 million shares at $5.50 per share. The company also priced a concurrent private placement of pre-funded warra
Fate Therapeutics Prices $100 Mln Of Public Offering, Concurrent Private Placement
No Data